FluMist

(redirected from Nasal-spray flu vaccine)

influenza vaccine (nasal)

(in-floo-en-za vak-seen) ,

FluMist

(trade name)

Classification

Therapeutic: vaccines immunizing agents
Pregnancy Category: C

Indications

Active live immunization for prevention of disease caused by Influenza A and B.

Action

Active immunization with live virus produces antibodies against Influenza.

Therapeutic effects

Decreased influenzal illness, with fewer days lost from school or work.

Pharmacokinetics

Absorption: Virus replicates in nasopharynx causing production of antibodies.
Distribution: Unknown.
Metabolism and Excretion: Unknown.
Half-life: Unknown.

Time/action profile

ROUTEONSETPEAKDURATION
Intranasalunknownunknownunknown

Contraindications/Precautions

Contraindicated in: Obstetric: Pregnancy; Hypersensitivity to FluMist, eggs, or egg products; History of asthma or reactive airways disease; Other live vaccine within 1 mo or inactivated vaccine within 2 weeks; Concurrent immunosuppressive therapy or disease causing immunosuppression or immunocompromise; Antiviral agents (not for 48 hr prior or 2 wk after); Pediatric: Children or adolescents (5–17 yr) receiving aspirin, aspirin-containing or salicylate therapy (risk of Reye syndrome); Chronic illness including cardiac/pulmonary disease, metabolic disease, renal impairment or hemoglobinopathy; History of Guillain-Barré.
Use Cautiously in: Obstetric / Pediatric: Lactation, children <2 yr, patients >50 yr (safety not established).

Adverse Reactions/Side Effects

Central nervous system

  • headache

Ear, Eye, Nose, Throat

  • rhinitis
  • nasal congestion

Miscellaneous

  • fever

Interactions

Drug-Drug interaction

Concurrent use of aspirin or salicylates in children/adolescents may ↑ risk of Reye syndrome.Concurrent antiviral therapy (may affect desired immune response to FluMist).

Route/Dosage

Intranasal (Adults and Children 9–49 yr) One dose (0.5 mL)/season.
Intranasal (Children 2–8 yr) Previously immunized with FluMist—one dose (0.2 mL)/season; not previously immunized with FluMist—two doses (0.2 mL each)/30 days apart for initial season.

Availability

Pre-filled single-use intranasal sprayer: 0.5 mL/sprayer, 0.2 mL/sprayer

Nursing implications

Nursing assessment

  • Assess patient for history of asthma or reactive airway disease. Patients with positive history should not receive FluMist.
  • Lab Test Considerations: Monitor patient for signs of allergic reaction (rash, pruritus, laryngeal edema, wheezing) following administration. Keep epinephrine, an antihistamine, and resuscitation equipment close by in case of an anaphylactic reaction.

Potential Nursing Diagnoses

Deficient knowledge, related to medication regimen (Patient/Family Teaching)

Implementation

  • Do not administer rimantidine or other antiviral agents within 48 hrs before or 2 wks after administration intranasal influenza virus vaccine (FluMist).
  • Store solution in refrigerator until just before use; do not freeze. Solution should be colorless to pale yellow and clear to slightly cloudy.
    • Do not administer FluMist concurrently with other vaccines, or in patients who have received a live virus vaccine within 1 mo or an inactivated vaccine within 2 wks of vaccination.
  • Intranasal: With the patient in an upright position, approximately 0.25 mL (half the dose of a single FluMist sprayer) is administered into each nostril. Insert the tip of the sprayer just inside the nostril and depress the plunger to spray. Remove the dose divider clip and administer the second half of the dose into the other nostril. Dispose of sprayer in routine for biohazard disposal.

Patient/Family Teaching

  • Explain to patient and parent the purpose of the vaccination.
  • Advise patient to avoid contact with patients who are immunocompromised for at least 21 days.

Evaluation/Desired Outcomes

  • Prevention of influenza resulting in fewer lost days from work and school.

FluMist

Influenza vaccine, live, intranasal.
Mentioned in ?
References in periodicals archive ?
Since 2003, our nasal-spray flu vaccine has been given to more than 75 million people to help prevent influenza.
FluMist Quadrivalent is the first and only needle-free, nasal-spray flu vaccine approved by the U.
There are two types of vaccines, the flu shot and the nasal-spray flu vaccine.
In fact, the first nasal-spray flu vaccine is now available.
There is a new nasal-spray flu vaccine that will probably be available for the 2001-2002 flu season.
Aetna (NYSE:AET) today announced that it will cover the nasal-spray flu vaccine FluMist(R) during the 2004-2005 flu season to enable more members to be vaccinated against influenza in the face of expected shortages of injectable influenza vaccine.
Coverage of nasal-spray flu vaccines for the 2004-2005 flu season is an exception to Aetna's coverage policy for influenza vaccine, and is provided per the terms of the member's specific benefit plan.
Another immunization choice, for some healthy people between ages of 5 and 49 years, is a nasal-spray flu vaccine commonly known as `FluMist.
FluMist, the nasal-spray flu vaccine -- a vaccine made with live, weakened flu viruses that do not cause the flu (sometimes called LAIV for "Live Attenuated Influenza Vaccine").
Aetna announced today that it will begin to cover the nasal-spray flu vaccine FluMist during the 2003-2004 flu season.
We encourage our members to learn more about this issue, as well as information on nasal-spray flu vaccines, by talking to their physician, visiting the Centers for Disease Control website (http://www.